Please login to the form below

Not currently logged in
Email:
Password:

tecemotide

This page shows the latest tecemotide news and features for those working in and with pharma, biotech and healthcare.

Merck makes $17bn play for Sigma-Aldrich

Merck makes $17bn play for Sigma-Aldrich

had something of a new product drought in recent years, compounded by late-stage failures including recent casualty tecemotide.

Latest news

  • Merck Serono pulls development of lung cancer prospect Merck Serono pulls development of lung cancer prospect

    The phase I/II trial, known as EMR 63325-009, compared tecemotide to placebo in patients on concurrent or sequential chemoradiotherapy. ... Results from the study suggested tecemotide had no effect on the primary endpoint of overall survival or any of

  • Developing therapeutic cancer vaccines Developing therapeutic cancer vaccines

    Tecemotide (Oncothyreon, Merck KGaA, Merck Serono) consists of mucin-1 (MUC-1), a cell surface glycoprotein that is over-expressed and structurally different in approximately 90 per cent of solid tumours ... Tecemotide is in global phase III development

  • Merck Serono puts faith in lung cancer candidate Merck Serono puts faith in lung cancer candidate

    The results of the START study found that tecemotide was unable to improve overall survival in patients with unresectable stage III NSCLC, the primary endpoint in the trial. ... Tecemotide (formerly known as Stimuvax and L-BLP25) is an immunotherapy

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    replacement etc will be sought. Oncothyreon's clinical stage pipeline includes the immunotherapy candidates tecemotide (phase III - Stage III non-small cell lung cancer) and ONT-10 (phase 1 - solid tumour

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics